Full Press Release Details
Files Provisional U.S. Patent Application for UroShield Ultra
Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness
N.Y., March 21, 2023 (Business Wire) -- NanoVibronix, Inc., (NASDAQ: NAOV) (the "Company"), a medical
device company utilizing the Company's proprietary and patented low intensity surface acoustic wave ("SAW") technology,
today announced it has filed a new provisional patent application with the United States Patent and Trademark Office ("USPTO")
entitled "Multiple Frequency Surface Acoustic Waves for Internal Medical Device" (the "Patent Application") related
Patent Application covers a recently developed enhancement to the UroShield product, UroShield "Ultra", which incorporates
improvements to the Company's original UroShield. The next generation UroShield Ultra includes modified housing that is designed
to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering
SAWs at multiple frequencies directly to indwelling catheters.
is, to our knowledge, the only proven, effective solution for the prevention of Catheter Associated Urinary Tract Infections ("CAUTI"),
the single highest source of hospital acquired infections," stated Brian Murphy, Chief Executive Officer of NanoVibronix. "This
new filing expands our portfolio of intellectual property assets and reinforces our competitive position. UroShield has been proven to
be instrumental in improving outcomes for hospital patients suffering from CAUTI. We are continually seeking opportunities to improve
our products and by employing cutting edge technology."
Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel,
focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology
allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption
of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of
medical professionals. The Company's primary products include PainShield , UroShield and WoundShield , all of which
are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix
is available at: www.nanovibronix.com.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance,
are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the
Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii)
negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv)
intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi)
product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or
inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain
and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare
system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components; (xii) the need
to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be
available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to
additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the
burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv)
market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of
forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including
the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to
read these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as
Maas, Managing Principal, Hayden IR, LLC